Previous close | 8.31 |
Open | 8.40 |
Bid | 9.05 x 0 |
Ask | 9.10 x 0 |
Day's range | 8.38 - 9.20 |
52-week range | 3.70 - 10.80 |
Volume | |
Avg. volume | 83,950 |
Market cap | 169.549M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.89 |
Earnings date | 19 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.23 |
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.